ClinicalTrials.gg
CompletedNCT00598559Updated Oct 21, 2016Results posted

Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

A Phase 3 interventional study of IV Acetaminophen in Acute Pain and Fever, sponsored by Mallinckrodt. Completed at 14 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing acetaminophen in Acute Pain — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Acute Pain.

Enrollment
9th of 21
213 · median 162
Started
2008
the only one that year
Phase 3
7 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
2 of 21
Mallinckrodt

Among the 21 studies testing acetaminophen in Acute Pain, this one is the 9th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 1st registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 21 studies testing acetaminophen in Acute Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 49 (48%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing acetaminophen in Acute Pain, or all of them as a file.
02

Study summary

The study will be investigating safety and efficacy administration of repeated dose of IV Acetaminophen (IV APAP) over five days for the treatment of acute pain or fever in adult patients.

Read the detailed description
  • To assess the safety of IV Acetaminophen when used over five days for the treatment of acute pain or fever in adult inpatients

Secondary Objectives:

  • To compare the efficacy of IV Acetaminophen 650 milligram (mg) every four (q4) hours vs. 1 gram (g) every 6 (q6) hours over 5 days of treatment
  • To compare the safety of IV Acetaminophen 650 mg q4 hours vs. 1 g q6 hours over 5 days of treatment
  • To compare the safety of IV Acetaminophen vs. standard of care (SOC) treatment over 5 days of treatment
  • To compare the efficacy of IV Acetaminophen vs. standard of care treatment over 5 days of treatment
03

Conditions studied

  • Acute Pain
  • Fever

Browse trials for

Keywords

  • Acute pain
  • Fever
  • IV Acetaminophen
  • Analgesic
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written prior to participation in the Study
  • Be at least 18 years of age and weigh at least 41 kilogram (kg)
  • Be anticipated by the Investigator to require multi-day (target is five days) use of IV treatment either because of having a "nothing by mouth" (NPO) status having a medical condition that makes oral intake difficult having a medical condition that requires IV treatment
  • Be willing to undergo 5 days of treatment with IV acetaminophen for the treatment of pain or fever (defined as a core temperature greater than or equal to 38 degrees celsius). Note that Subjects have a slightly less than 15% chance (one in seven) of being assigned to the Control Group and receiving standard of care treatment, but no IV APAP.
  • Have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff
  • If a female of child bearing potential, have a negative pregnancy test within 48 hours of randomization

Exclusion criteria

Exclusion Criteria:

  • Has a significant medical disease, laboratory abnormality or condition that, in the Investigator's judgment, could compromise the Subject's welfare or would otherwise contraindicate Study participation
  • Is expected to have difficulty in communicating with the Study staff or completing Study requirements (including follow up visits)
  • Has known to acetaminophen or the inactive ingredients () of IV acetaminophen or any to receiving acetaminophen
  • Has impaired liver function, e.g., (ALT) greater than or equal to 3 times the (ULN), greater than or equal to 3 times ULN, known active hepatic disease (e.g., hepatitis), evidence of chronic liver disease or other condition affecting the liver (e.g., alcoholism as defined by , cirrhosis or chronic hepatitis)
  • Has participated in an interventional clinical Study ( or marketed product) within 30 days of Study entry
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    1 g IV Acetaminophen

    1 g q6h IV Acetaminophen

    Drug: IV Acetaminophen

  • Experimental
    650 mg IV Acetaminophen

    650 mg q4h IV Acetaminophen

    Drug: IV Acetaminophen

  • Other
    Standard of Care

    The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.

    Drug: IV Acetaminophen

Interventions

  • Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.

    Also known as: IV Acetaminophen (IV APAP)

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).

    Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).

    Time frame: T0 (first dose of IV APAP or randomization to SOC group) to Day 7 - 12 Follow-up

  2. Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)

    Serious TEAE is any untoward medical occurrences at any dose of study medication that: * results in death * is life threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

    Time frame: First dose (T0) to within 30 days of the last dose of study medication.

Secondary outcomes

  1. Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments

    Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with side effects related to study treatment at End of Day 5 (prior to discharge)

    Time frame: End of Day 5 (prior to discharge)

  2. Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.

    Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with study treatments looking back over the entire treatment period was conducted at Day 7.

    Time frame: Study period lookback at Day 7

07

Results

Posted Dec 10, 2010
Limitations and caveats
No separate efficacy analyses were performed for the fever because only 1 subject in each active group had fever as an indication, and no subject had both pain and fever as indications for treatment with IV acetaminophen.

Participant flow

Open label study conducted in the US from 21 Feb 2008 -12 Aug 2008

Participant flow — Overall Study
MilestoneIV Acetaminophen 1 Gram Every 6 HoursIV Acetaminophen 650 Milligram Every 4 HoursStandard of Care (SOC)
Started929130
Completed656327
Not completed27283
Withdrew: Adverse event1170
Withdrew: Withdrawal by subject220
Withdrew: Protocol non-compliance100
Withdrew: Early discharge from hospital9123
Withdrew: Subject unable/unwilling to attend visit470

Outcome measures

SecondarySubject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments

Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with side effects related to study treatment at End of Day 5 (prior to discharge)

Time frame:
End of Day 5 (prior to discharge)
Reported as:
Mean · Units on a scale
Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments
Units on a scaleIV Acetaminophen 1 g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)
Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments2.5 ± 0.782.5 ± 0.672.0 ± 0.85
PrimaryNumber of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).

Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).

Time frame:
T0 (first dose of IV APAP or randomization to SOC group) to Day 7 - 12 Follow-up
Reported as:
Number · Participants
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).
ParticipantsIV Acetaminophen 1 g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).778626
PrimarySubjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)

Serious TEAE is any untoward medical occurrences at any dose of study medication that: * results in death * is life threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

Time frame:
First dose (T0) to within 30 days of the last dose of study medication.
Reported as:
Number · Participants
Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)
ParticipantsIV Acetaminophen 1 g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)
Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)14113
SecondarySubject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.

Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with study treatments looking back over the entire treatment period was conducted at Day 7.

Time frame:
Study period lookback at Day 7
Reported as:
Mean · Units on a scale
Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.
Units on a scaleIV Acetaminophen 1 g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)
Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.2.4 ± 0.752.3 ± 0.742.2 ± 0.61

Adverse events

Collected over AEs were collected after the start of study medication (T0) until approximately 7 days after the last dose for IVAPAP group or 12 days from T0 for SOC group. SAEs were collected from first dose until 30 days fter the last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Acetaminophen 1 Gram Every 6 Hours—14/92 (15.2%)60/92 (65.2%)
IV Acetaminophen 650 Milligram Every 4 Hours—11/91 (12.1%)68/91 (74.7%)
Standard of Care (SOC)—3/30 (10%)18/30 (60%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventIV Acetaminophen 1 Gram Every 6 HoursIV Acetaminophen 650 Milligram Every 4 HoursStandard of Care (SOC)
DyspnoeaRespiratory, thoracic and mediastinal disorders0/920/911/30
Postoperative ileusInjury, poisoning and procedural complications0/921/911/30
SepsisInfections and infestations0/920/911/30
Hepatic enzyme increasedInvestigations0/922/910/30
Postoperative wound infectionInfections and infestations2/922/910/30
AbscessInfections and infestations0/921/910/30
Gastric ulcer haemorrhageGastrointestinal disorders0/921/910/30
HaematomaVascular disorders0/921/910/30
Multi-organ failureGeneral disorders1/921/910/30
Myocardial infarctionCardiac disorders1/921/910/30
Most frequent other events
Showing 10 of 20
Most frequent other events
EventIV Acetaminophen 1 Gram Every 6 HoursIV Acetaminophen 650 Milligram Every 4 HoursStandard of Care (SOC)
NauseaGastrointestinal disorders23/9234/918/30
ConstipationGastrointestinal disorders18/9221/915/30
AnaemiaBlood and lymphatic system disorders11/9210/916/30
InsomniaPsychiatric disorders13/9217/915/30
PruritusSkin and subcutaneous tissue disorders11/9213/912/30
HeadacheNervous system disorders7/925/914/30
VomitingGastrointestinal disorders6/9210/911/30
HypokalaemiaMetabolism and nutrition disorders10/924/912/30
AnxietyPsychiatric disorders4/922/913/30
HypotensionVascular disorders7/929/912/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IV Acetaminophen 1g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)Total
<=18 years0000
Between 18 and 65 years485417119
>=65 years44371394
Sex: Female, Male
Sex: Female, Male(Participants)IV Acetaminophen 1g q6hIV Acetaminophen 650 mg q4hStandard of Care (SOC)Total
Female494417110
Male434713103
08

Study locations

14 sites
  • Arcadia Methodist Hospital
    Arcadia, California 91007, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Accurate Clinical Trials, Inc.
    Laguna Hills, California 92653, United States
  • Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • Lotus Clinical Research, Inc.
    Pasadena, California 91105, United States
  • Santa Barbara Cottage Hospital
    Santa Barbara, California 93105, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • G&G Research
    Fort Pierce, Florida 34950, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health Science University
    Portland, Oregon 97239, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Memorial Herman/Memorial City Hospital
    Houston, Texas 77024, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 2 years 1 month after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2008
First posted
Jan 22, 2008
Start
Jan 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Apr 3, 2009
Results first posted
Dec 10, 2010
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00598559
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jan 22, 2008
Start date
Jan 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 10, 2010
Last update
Oct 21, 2016

Study contacts

Eugene Viscusi, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion